Ophthalmic Research
Original Paper
CMDBS, Functional Analogue of Heparin Sulfate as a New Class of Corneal Ulcer Healing AgentsFredj-Reygrobellet D.a · Hristova D.L.b · Ettaiche M.c · Meddahi A.d · Jozefonwicz J.e · Barritault D.daHistology II, School of Medicine, Nice, France; bDepartment of Ophthalmology, School of Medicine, Sofia, Bulgaria; cPharmacology, School of Medicine, Nice, France; dCRET, Paris XII, France; eLaboratoire de Recherche sur les Macromolécules, Paris, France
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: January 14, 1994
Accepted: June 30, 1994
Published online: December 11, 2009
Issue release date: 1994
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0
ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)
For additional information: https://www.karger.com/ORE
Abstract
Soluble dextran polymer derivatives (CMDBSs) are originally synthesized as heparin-like plasma substitutes. Some of them mimic heparin in its interactions and stabilize, protect and facilitate actions of heparin binding growth factors. The wound healing activity of one specific CMDBS was studied in a model of corneal ulcer on the rabbit eye and compared with the activity of basic fibroblast growth factors (bFGF) added alone or in association with CMDBS. Total reepithelialization was observed with bFGF + CMDBS, bFGF alone and CMDBS alone after, respectively, 3.8 ± 0.78, 4.3 ± 0.67 and 4.4 ± 0.51 days. All treatments were efficient if compared with eyes treated with saline (p < 0.0001). The grade of significance of the applied treatments was as follows: bFGF + CMDBS > bFGF > CMDBS > saline. Our study pinpoints that some specific CMDBS are as potent agents as bFGF for corneal ulcer healing, and can therefore be proposed for therapeutic use.
© 1994 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Received: January 14, 1994
Accepted: June 30, 1994
Published online: December 11, 2009
Issue release date: 1994
Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0
ISSN: 0030-3747 (Print)
eISSN: 1423-0259 (Online)
For additional information: https://www.karger.com/ORE
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission